Barclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Equal-Weight rating on BioCryst Pharma (NASDAQ:BCRX) and raises the price target from $6 to $7.
August 06, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Gena Wang maintains an Equal-Weight rating on BioCryst Pharma and raises the price target from $6 to $7.
The raised price target from $6 to $7 by Barclays suggests a positive outlook for BioCryst Pharma, which could lead to a short-term increase in stock price. However, the Equal-Weight rating indicates a neutral stance, balancing the impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100